1. Introduction {#s0005}
===============

Bacterial meningitis is caused by *Streptococcus pneumoniae* and *Neisseria meningitidis* in 85% of cases [@bb0005], [@bb0010]. *Listeria monocytogenes* is the third most common cause of bacterial meningitis (identified in 6% of cases) and is associated with high mortality and rate of unfavorable outcome [@bb0015], [@bb0020]. Listeria meningitis is predominantly found in elderly and immunocompromised patients, but also occurs in previous healthy adults [@bb0025], [@bb0030]. In an explorative study we assess the associations between cerebrospinal fluid (CSF) inflammatory markers and outcome in Listeria meningitis.

2. Materials and methods {#s0010}
========================

We identified adults (\> 16 years of age) who had Listeria meningitis established by positive CSF culture and were listed in the database of the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM) from March 2006 to April 2012. This laboratory receives CSF isolates from approximately 85% of all patients with bacterial meningitis in the Netherlands. Patients or their legal representatives received written information concerning the study and were asked to give written informed consent for participation. Patients with negative CSF cultures, hospital-acquired bacterial meningitis, or neurosurgical devices, and those within 1 month following neurosurgical procedure or neurotrauma, were excluded. The study was approved by the Medical Ethics Committee of the Academic Medical Center, University of Amsterdam, the Netherlands.

Online case record forms were used to collect data on clinical features, complications, treatment and outcome in adults with meningitis. Patients with an altered immune status owing to splenectomy, diabetes mellitus, cancer, alcoholism or the use of immunosuppressive drugs were considered immunocompromised, as were patients infected with HIV. Neurological examination was performed at discharge and outcome was scored according to the Glasgow Outcome Scale. This measurement scale is well validated, with scores varying from 1 (death) to 5 (good recovery) [@bb0035]. A favorable outcome was defined as a score of 5, and an unfavorable outcome was defined as a score of 1--4.

In patients with Listeria meningitis, residual CSF from the diagnostic lumbar puncture was collected, centrifuged, and supernatant was aliquoted and stored at − 80 °C until analysis. Control CSF samples were collected from 19 patients in whom a lumbar puncture was performed to rule out sub-arachnoid hemorrhage in patients eventually diagnosed with benign thunderclap headache. All these CSF samples had normal leukocyte count, total protein level and glucose concentration ([Appendix A1](#t0010){ref-type="table"}). CSF cytokine, chemokine and complement factor concentrations were determined with Luminex technology using a Milliplex MAP assay, Millipore, Billerica, MA, USA. For complement component C3a, iC3b, C5a and sC5b-9 levels the Microvue C3a, iC3b, C5a and sC5b-9 Quidel ELISA kits, Quidel, San Diego, USA were used. CSF complement component levels of C1q and MBL were measured using the Hycult ELISA kits, Hycult Biotech, Uden, the Netherlands and PAI-2 was measured using the USCN ELISA kit, USCN Life Sciences, Hubei, China.

Cytokine, chemokine and complement factor levels were compared between negative controls and patients with Listeria meningitis and subsequently between patients with Listeria meningitis with an unfavorable outcome and those with a favorable outcome. The Mann--Whitney *U*-test was used to examine associations between cytokine, chemokine and complement factor levels between groups. All statistical tests were two-tailed, and for differences between negative controls and patients a Bonferroni corrected p-Value below \< .00051 was considered significant. In the comparison between patients with a favorable and unfavorable outcome the limited number of patients prevented correction for multiple testing. Therefore, we described biomarkers with P value \< .01. All statistical analyses were performed with SPSS version 19.0.

3. Results {#s0015}
==========

From March 2006 to April 2012, 62 patients with Listeria meningitis were identified of 1032 included episodes of bacterial meningitis (6%). CSF was available for 26 patients (42%), with median age of 68 years (interquartile range \[IQR\] 57--74). Patients for whom CSF was available had higher scores on the Glasgow Coma Scale on admission compared to those in whom CSF was not available (GCS 14 \[IQR 11--15\] *vs.* 11 \[IQR 10--14\], P = .03); other clinical and laboratory characteristics and outcome were comparable between patients with and without CSF available.

[Table 1](#t0005){ref-type="table"} shows the clinical and laboratory characteristics of 26 patients with CSF available. The majority was male (77%) and 15 patients (58%) had an immunocompromised state. Three patients (13%) were not immunocompromised and were 50 years old or younger. Median CSF leukocyte count was 766 cells/mL (interquartile range \[IQR\] 255--2047), protein level of 2.4 g/L (IQR 1.8--3.8) and CSF to blood glucose ratio of 0.27 (IQR 0.16--0.39). Adjunctive dexamethasone treatment was started with or before the first dose of antibiotics in 14 patients (54%) according to the standard regimen of 10 mg every 6 h for 4 days. Data on diagnostic sequence of cranial CT, lumbar puncture and initiation of treatment were available for 20 patients. In 19 patients a cranial CT was made prior to the lumbar puncture, and in only 6 the antibiotic treatment was initiated before the CT. Fifteen patients (58%) had an unfavorable outcome and 6 (23%) died.

Because of limited amounts of cerebrospinal fluid not all assays could be performed for all patients: sufficient CSF to assess 46 analytes was available from all 26 patients and 19 controls. The other 55 analytes were tested in 19--25 patients and 13--18 controls ([Appendix A2](#t0015){ref-type="table"}). Out of 101 analytes, 10 (10%) were below the lower limit of detection in all patient and control samples (IL-9, CCL1, CCL21, IL-33, LIF, TPO, TSLP, MMP-12, MMP-13 and MMP-7). For 21 analytes (21%) the protein concentration was below the lower limit of detection in all negative control samples, but detectable concentrations were present in Listeria meningitis patients. Compared to negative controls, 51 of the 101 (50%) cytokines, chemokines and complement factors were significantly elevated in patients with Listeria meningitis after Bonferroni correction (\< 0.00051) for multiple testing.

We identified vascular endothelial growth factor (VEGF; P = .001, [Appendix A3](#t0020){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"}), and ([Appendix A4](#t0025){ref-type="table"}) complement component C3a (P = .002), soluble interleukin receptor antagonist a2 (sIL-2Rα; P = .002), chemokine (C--X--C motif) ligand 7 (CXCL7; P = .003), CX3CL1 (P = .003), CCL11 (P = .005), interferon alpha2 (IFN-α2; P = .005), chemokine (C--C motif) ligand 20 (CCL20; P = .007), interleukin 12 subunit p40 (IL-12p40; P = .008), soluble CD40 ligand (sCD40L; P = .008) and interleukin 18 (IL-18; P = .008) as the top 11 cytokines, chemokines and complement factors with the strongest association (P \< .01) with unfavorable outcome in patients with Listeria meningitis.

No differences in CSF biomarker levels were identified when comparing patients in whom the lumbar puncture was performed before or after parenteral antibiotics.

4. Discussion {#s0020}
=============

In our explorative study we assessed 101 cytokines, chemokines and complement factors and found that VEGF, C3a, sIL-2Rα, CXCL7, CX3CL1, CCL11, IFN-α2, CCL20, IL-12p40, IL-18, and sCD40L were most significantly different between Listeria meningitis patients with an unfavorable and those with a favorable outcome. These differences in protein levels may reflect important pathways in the pathophysiology of Listeria meningitis contributing to disease severity. VEGF, sIL-2Rα, C3a and IFN-α2 have previously been identified to be involved in the host defense mechanisms against *L. monocytogenes* [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060].

VEGF is a growth factor and an angiogenic cytokine which is expressed intracellularly in several cell types, such as macrophages, inside which *L. monocytogenes* replicate [@bb0040], [@bb0065]. *In vitro* experiments have previously shown that VEGF levels in RAW264.7 macrophage-like cells were elevated following stimulation with heat-killed *L. monocytogenes* [@bb0045]. Furthermore, an *in vivo* model showed elevated expression of VEGF in splenic macrophages in mice with *L. monocytogenes* compared to negative controls [@bb0075]. This production of VEGF is induced by CXCL7 [@bb0075], which was also elevated in patients with an unfavorable outcome. VEGF has been shown to induce endothelial changes during bacterial meningitis in patients and disrupt the blood brain barrier in a rat model [@bb0080]; thereby increasing brain inflammation and oedema. Elevated VEGF levels, mediated by CXCL7, could result in increased brain damage in patients explaining the increased rate of unfavorable outcome.

C3a is an anaphylatoxin, causing attraction of phagocytic cells, recruits antibodies and initiates the adaptive immune response [@bb0085]. A study on the role of the complement in *L. monocytogenes* infections showed that listerial opsonization mainly depended on the classical complement pathway [@bb0090]. Following opsonization, activation of the final common pathway results in conversion of C3 to C3a and C3b [@bb0050], [@bb0085]. The degree of complement activation has previously been shown to influence outcome in pneumococcal meningitis by aggravating brain damage [@bb0095]. In a pneumococcal meningitis mouse model inhibition of complement factor 5 was shown to improve outcome [@bb0095]. The elevated C3a levels in patients with unfavorable outcome suggest that complement activation is detrimental in Listeria meningitis as well. Whether complement inhibition is a successful strategy in Listeria meningitis is an interesting topic for experimental studies.

Several proteins that were elevated in patients with an unfavorable outcome were involved in T-cell activation. We observed elevated levels of sIL-2Rα, sCD40L and IL-12p40 in patients with an unfavorable outcome indicating a strong T-cell activation, which has been shown to be crucial in the immune response to *L. monocytogenes* in mouse models [@bb0100]. Activated T-cells express high affinity receptors for interleukin-2, which plays an important role during proliferation of T-lymphocytes. This IL-2-receptor alpha is also released in a soluble form (sIL-2Ra), which is considered to be an important marker of continuous T-cell activation [@bb0105], [@bb0110]. Another protein in the activation of T-cells which was elevated in patients with an unfavorable outcome is sCD40L, which is a member of the TNF family and results in T-cell priming following infection with *L. monocytogenes* [@bb0115]. IL-12p40 is important for sustaining a sufficient number of memory/effector Th1 cells to mediate long-term protection to intracellular pathogens, and acts on T-cells and natural killer cells, which are both essential to combat *L. monocytogenes* infection [@bb0120].

Other proteins that were identified to be elevated in patients with unfavorable outcome were interferon (IFN-α2) or interferon-related (IL-18, CX3CL1, CCL20). Type 1 interferons, which include interferon alpha, have been shown to have a deleterious effect during *L. monocytogenes* infection by decreasing the viability of infected macrophages [@bb0120], [@bb0125]. The increased levels of IFN-α2 in patients with an unfavorable outcome concur with these experimental studies. IFN-γ on the other hand is essential during *L. monocytogenes* infection, and provides early protection against the pathogen [@bb0120]. IL-18 a pro-inflammatory cytokine that stimulates IFN-γ production in T-helper type 1 cells and NK cells [@bb0130]. CX3CL1 and CCL20 are chemo-attractants that are produced following stimulation by IFN-γ and result in the recruitment of monocytes, NK cells and T-cells [@bb0135]. The higher levels of IL-18, CX3CL1 and CCL20 were not paralleled by significantly elevated levels of IFN-γ in patients with an unfavorable outcome.

CCL11 (Eotaxin) is an eosinophil specific chemokine assumed to be involved in eosinophilic inflammatory diseases. CCL11 production is not related to interferons and does not influence T-cell activation [@bb0140]. Its role in *L. monocytogenes* infection has not been studied, and it is unclear how the elevated levels of CCL11 in patients with an unfavorable outcome must be interpreted.

Our study has several limitations. First, only patients with a positive CSF culture for *L. monocytogenes* were included in this study. Negative CSF culture results occur in 11%--30% of patients with bacterial meningitis, and this percentage may be higher in patients with Listeria meningitis [@bb0005], [@bb0030], [@bb0145], [@bb0150]. Therefore, these patients are underrepresented in our cohort. Second, as shown in [Table 1](#t0005){ref-type="table"}, for the 26 patients we analyzed their cytokine levels had a higher Glasgow Coma Scale compared to 36 patients for whom no CSF was available. This implies a selection towards less severe diseases in the studied population compared to the general population of Listeria meningitis patients. Third, the number of patients is insufficient to correct for multiple testing in the analysis for outcome or perform multivariate analyses. Therefore, the results must be interpreted with caution, as type 1 errors may occur due to the high number of variables tested, and validation of our results in other cohorts is warranted. Fourth, the number of patients is insufficient to analyze if the expression of biomarkers was influenced in subcategories such as the immune state of the patients, or patients with systemic of neurological complications. Finally, it remains unclear whether the identified proteins have a causative role in the development of unfavorable outcome or merely reflect increased disease severity. Despite these limitations, this study on CSF characteristics culture confirmed that Listeria meningitis is the largest series so far and gives insight in the pathophysiology of the disease.

5. Conclusions {#s0025}
==============

Our data suggest that VEGF production (VEGF, CXCL7), complement activation (C3a), T-lymphocyte activation (sIL-2Rα, sCD40L, IL-12p40), and interferon production (IFN-α2, IL-18, CCL20, CX3CL1) are the most important elements of the immune response during Listeria meningitis, and may influence outcome. These data may give leads to further investigation in the pathophysiology of Listeria meningitis.
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Appendix A1Clinical and laboratory characteristics of 26 patients in whom cytokine levels were analyzed in CSF *vs.* 36 patients in whom cytokine levels were not analyzed in CSF. All 62 adults had community-acquired Listeria meningitis and were included in the prospective cohort study between 2006 and 2012[a](#tf0010){ref-type="table-fn"}.VariablePatients with CSF collection for analysis N = 26 (%)Patients without CSF collection for analysis N = 36 (%)p-ValueMedian age in years (IQR)68 (57--74)73 (62--77)0.34Male sex20 (77)19 (53)0.05Immunocompromised15 (58)29 (81)0.05Duration of symptoms \< 24 h8 (31)12 (33)0.83Glasgow Coma Scale (IQR)14 (11--15)11 (10--14)0.03 \< 14 (indicating change in mental status)13 (50)25 (69)0.12 ≤ 8 (indicating coma)1 (4)4 (11)0.39Indexes of CSF inflammation WBC count (cells/mL)766 (225--2047)636 (367--1498)0.89 \< 1000 cells/mL15 (58)24 (67)0.47 Protein level (g/L)2.4 (1.8--3.8)2.6 (1.7--3.5)0.99 CSF to blood glucose ratio0.27 (0.16--0.39)0.24 (0.06--0.34)0.44Dexamethasone treatment14 (54)19 (53)0.92Unfavorable outcome15 (58)23 (64)0.62Death6 (23)16 (44)0.08[^1]

Appendix A2Out of 101 cytokines, chemokines and complement factors, 73 were significantly elevated compared to negative controls. 51 were significantly elevated after Bonferroni correction.VariableN (LM/NC)[a](#tf0015){ref-type="table-fn"}*L. monocytogenes* meningitis\
Median level (IQR)Negative controls\
Median level (IQR)p-ValueEGF26/19151 pg/ml (62--313)81 pg/ml (45--126)0.012CCL1126/19448 pg/ml (200--773)81 pg/ml (28--126)\< 0.0001[b](#tf0020){ref-type="table-fn"}FGF226/19962 pg/ml (584--1387)484 pg/ml (136--731)\< 0.0001[b](#tf0020){ref-type="table-fn"}Flt3-Lig26/19250 pg/ml (98--290)71 pg/ml (41--133)0.002CX3CL126/191.3 ng/ml (0.8--12)0.5 ng/ml (0.4--0.7)\< 0.0001[b](#tf0020){ref-type="table-fn"}GCSF26/1911.3 ng/ml (5.4--16.5)0.06 ng/ml (0.04--0.1)\< 0.0001[b](#tf0020){ref-type="table-fn"}GMCSF26/19269 pg/ml (119--1054)18 pg/ml (9--31)\< 0.0001[b](#tf0020){ref-type="table-fn"}CXCL126/192.2 ng/ml (1.3--5.0)0.06 ng/ml (0.02--0.09)\< 0.0001[b](#tf0020){ref-type="table-fn"}IFN-α226/19938 pg/ml (628--1602)67 pg/ml (7--125)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-1a26/19454 pg/ml (319--2420)18 pg/ml (11--21)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-1b26/19189 pg/ml (91--492)4 pg/ml (2--6)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-1ra26/192.3 ng/ml (982--4305)0.02 ng/ml (0.008--0.03)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-226/1936 pg/ml (25--94)4 pg/ml (3--7)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-326/1915 pg/ml (8--31)15 pg/ml (7--29)0.696IL-426/1970 pg/ml (35--101)82 pg/ml (25--116)0.836IL-526/1910 pg/ml (6--15)3.8 pg/ml (1.7--7.4)0.001IL-626/1958 ng/ml (26--89)0.01 ng/ml (0.009--0.03)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-726/19163 pg/ml (95--1251)92 pg/ml (25--139)0.002IL-826/1911 ng/ml (5.6--19)0.02 ng/ml (0.02--0.04)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-926/1975 pg/ml (29--132)42 pg/ml (22--83)0.118IL-1026/19408 pg/ml (171--1080)3.7 pg/ml (1.8--6.4)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-12p4026/19338 pg/ml (213--1228)69 pg/ml (12--103)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-12p7026/19141 pg/ml (77--207)19 pg/ml (13--29)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-1326/1931 pg/ml (12--55)11 pg/ml (5--28)0.015IL-1526/1953 pg/ml (25--83)22 pg/ml (15--34)0.005IL-1726/1938 pg/ml (18--95)4.8 pg/ml (3.2--5.3)\< 0.0001[b](#tf0020){ref-type="table-fn"}CCL226/1917 ng/ml (5.7--69)0.5 ng/ml (0.4--0.6)\< 0.0001[b](#tf0020){ref-type="table-fn"}CCL726/19951 pg/ml (489--3556)114 pg/ml (59--167)\< 0.0001[b](#tf0020){ref-type="table-fn"}CCL2226/19951 pg/ml (362--1232)707 pg/ml (230--883)0.093CCL326/19209 pg/ml (126--520)125 pg/ml (51--142)0.001CCL426/191.5 ng/ml (0.6--4.2)0.6 ng/ml (0.3--0.8)\< 0.0001[b](#tf0020){ref-type="table-fn"}PDGFABBB26/19158 pg/ml (58--333)73 pg/ml (48--123)0.066CCL526/1964 pg/ml (27--202)20 pg/ml (10--29)0.002sCD40L26/19381 pg/ml (206--841)76 pg/ml (50--104)\< 0.0001[b](#tf0020){ref-type="table-fn"}sIL-2Rα26/19186 pg/ml (85--491)55 pg/ml (24--96)\< 0.0001[b](#tf0020){ref-type="table-fn"}TGFα26/1917 pg/ml (7--32)16 pg/ml (10--26)0.597TNFα26/19319 pg/ml (212--639)50 pg/ml (32--61)\< 0.0001[b](#tf0020){ref-type="table-fn"}TNFβ26/1943 pg/ml (20--441)15 pg/ml (10--24)0.001VEGF26/191.2 ng/ml (0.7--1.9)0.5 ng/ml (0.4--0.7)\< 0.0001[b](#tf0020){ref-type="table-fn"}IL-1826/196.9 ng/ml (4.8--18)0.7 ng/ml (0.4--0.9)\< 0.0001[b](#tf0020){ref-type="table-fn"}vWFAg17/123 pg/ml (2--9)0.4 pg/ml (0.11--0.51)\< 0.0001[b](#tf0020){ref-type="table-fn"}Fibrinog\\en17/120.55 pg/ml (0.2--0.6)0.05 pg/ml (0.03--0.06)\< 0.0001[b](#tf0020){ref-type="table-fn"}TAFI17/121.3 pg/ml (0.8--2.5)0.38 pg/ml (0.11--0.54)0.002CCL819/187.8 ng/ml (4.1--35)0.1 ng/ml (0.09--0.2)\< 0.0001[b](#tf0020){ref-type="table-fn"}CCL1319/18301 pg/ml (103--392)333 pg/ml (200--436)0.313ENA-7819/18470 pg/ml (378--701)577 pg/ml (271--733)0.775CXCL1219/182.3 ng/ml (1163--3824)2.0 ng/ml (0.9--3.2)0.538CXCL1319/1816 pg/ml (8--29)2.9 pg/ml (0.6--6.5)\< 0.0001[b](#tf0020){ref-type="table-fn"}CCL119/1828 pg/ml (10--57)47 pg/ml (29--65)0.092IL-1619/18247 pg/ml (64--46)280 pg/ml (176--459)0.799MIP-1d19/18501 pg/ml (146--710)88 pg/ml (35--121)\< 0.0001[b](#tf0020){ref-type="table-fn"}CCL1719/182.7 pg/ml (1.1--4.2)1.7 pg/ml (0.7--2.5)0.092CCL2119/18698 pg/ml (374--871)714 pg/ml (482--922)0.558CCL2419/1854 pg/ml (21--84)24 pg/ml (10--29)0.008CCL2619/1857 pg/ml (35--144)41 pg/ml (27--78)0.210CCL2719/1825 pg/ml (6--61)8 pg/ml (6--12)0.053IL-2319/18233 pg/ml (144--463)234 pg/ml (143--443)0.893LIF19/18599 pg/ml (346--734)636 pg/ml (439--828)0.313TPO19/18932 pg/ml (513--1299)968 pg/ml (328--1747)0.822TRAIL19/18151 pg/ml (68--229)10 pg/ml (4--23)\< 0.0001[b](#tf0020){ref-type="table-fn"}SCF19/1840 pg/ml (25--73)21 pg/ml (10--27)0.001TSLP19/1873 pg/ml (52--97)45 pg/ml (23--85)0.16IL-2019/181.7 ng/ml (1.4--2.7)1.5 ng/ml (0.9--2.6)0.27IL-2119/1841 pg/ml (25--67)20 pg/ml (3--41)0.020IL-28A19/1882 pg/ml (40--108)68 pg/ml (34--102)0.46IL-3319/18138 pg/ml (87--163)78 pg/ml (34--148)0.06MCSF19/1828 ng/ml (13--37)1.5 ng/ml (1.2--2.7)\< 0.0001[b](#tf0020){ref-type="table-fn"}CXCL719/185.1 ng/ml (2.6--8.3)0.5 ng/ml (0.09--0.6)\< 0.0001[b](#tf0020){ref-type="table-fn"}CXCL619/18258 pg/ml (164--1172)18 pg/ml (11--25)\< 0.0001[b](#tf0020){ref-type="table-fn"}CCL14a19/187.5 ng/ml (4.3--13)1.2 ng/ml (0.9--18)\< 0.0001[b](#tf0020){ref-type="table-fn"}CCL1919/18153 pg/ml (76--303)79 pg/ml (38--98)0.003CCL2019/18779 pg/ml (280--1857)23 pg/ml (10--28)\< 0.0001[b](#tf0020){ref-type="table-fn"}XCL119/181.3 ng/ml (0.4--1.5)0.6 ng/ml (0.2--0.8)0.007IL-1119/183.2 ng/ml (1.8--4.4)2.1 ng/ml (1.3--2.7)0.026IL-2919/183.3 ng/ml (1.5--4.3)1.2 ng/ml (0.5--2.1)0.004MMP-326/1823 ng/ml (10--39)1 ng/ml (0.7--1.9)\< 0.0001[b](#tf0020){ref-type="table-fn"}MMP-1226/186 ng/ml (4.1--9)7.8 ng/ml (4--13.4)0.34MMP-1326/184.6 ng/ml (2.4--6.7)4.9 ng/ml (1.6--8.4)0.63CFH25/187 ng/ml (4.8--9.1)1.1 ng/ml (0.9--1.5)\< 0.0001[b](#tf0020){ref-type="table-fn"}MMP-125/18683 pg/ml (216--937)333 pg/ml (158--594)0.030MMP-225/1817 ng/ml (7.7--32)26 ng/ml (9.7--33)0.46MMP-725/1810 ng/ml (4.9--16)128 ng/ml (7.1--160)0.56MMP-925/18387 ng/ml (120--497)0.1 ng/ml (0.06--0.2)\< 0.0001[b](#tf0020){ref-type="table-fn"}MMP-1025/18266 pg/ml (154--275)114 pg/ml (65--190)0.003ICAM26/1964 pg/ml (46--121)2.3 pg/ml (1.0-5.1)\< 0.0001[b](#tf0020){ref-type="table-fn"}tPAI-126/1950 ng/ml (28--83)0.8 ng/ml (0.6--1.8)\< 0.0001[b](#tf0020){ref-type="table-fn"}MIF26/131.5 ng/ml (0.6-5.1)0.8 ng/ml (0.6--1.6)0.16C3a25/19171 pg/ml (112--369)5.8 pg/ml (4--9)\< 0.0001[b](#tf0020){ref-type="table-fn"}iC3b25/1915 pg/ml (8--21)3.5 pg/ml (2.7--4.7)\< 0.0001[b](#tf0020){ref-type="table-fn"}C5a18/143.2 pg/ml (1.1-8.8)0 pg/ml (0--0.4)\< 0.0001[b](#tf0020){ref-type="table-fn"}C5b918/14415 pg/ml (95--1294)155 pg/ml (64--394)0.14IFN-γ26/191.1 ng/ml (2.4-19)0.02 ng/ml (0.009--0.03)\< 0.0001[b](#tf0020){ref-type="table-fn"}CXCL919/1881 ng/ml (21--357)0.12 ng/ml (0.04--0.17)\< 0.0001[b](#tf0020){ref-type="table-fn"}CXCL1026/19488 ng/ml (485--488)0.4 ng/ml (0.1--0.7)\< 0.0001[b](#tf0020){ref-type="table-fn"}PDGFAA26/1978 pg/ml (54--176)50 pg/ml (21--73)0.001CXCL1119/1815 ng/ml (4.3--25)0.01 ng/ml (0.008--0.02)\< 0.0001[b](#tf0020){ref-type="table-fn"}C325/187.6 ng/ml (0.1--12)1.8 ng/ml (0.2--5.4)0.008VCAM26/19394 pg/ml (290--527)42 pg/ml (34--51)\< 0.0001[b](#tf0020){ref-type="table-fn"}PAI-226/14240 ng/ml (168--319)18 ng/ml (0.3--27)\< 0.0001[b](#tf0020){ref-type="table-fn"}MBL21/1911 ng/ml (3.9--17)3 ng/ml (2--3.8)\< 0.0001[b](#tf0020){ref-type="table-fn"}C1q21/19152 ng/ml (118--245)114 ng/ml (75--139)0.009[^2][^3]

Appendix A3Top 11 cytokines, chemokines and complement factors with strongest association with an unfavorable outcome in patients with Listeria meningitis.Cytokine, chemokine or complement factorUnfavorable outcome (n = 15)\
Median level (IQR)[a](#tf0025){ref-type="table-fn"}Favorable outcome (n = 11)\
Median level (IQR)p-ValueVEGF1.2 ng/ml (1.7--2.3)0.8 ng/ml (0.2--1.1).001C3a9.1 μg/ml (5.8--10.7)3.2 μg/ml (1.7--5.2).002sIL-2Rα338 pg/ml (139--500)112 pg/ml (62--170).002CXCL7426 pg/ml (159--573)119 pg/ml (64--159).003CX3CL17.6 ng/ml (1.2--13.9)0.8 ng/ml (0.6--1.3).003CCL11688 pg/ml (442--942)292 pg/ml (153--425).005IFN-α21.4 ng/ml (0.9--2.0)0.7 ng/ml (0.3--0.9).005CCL202.2 ng/ml (1.2--4.8)0.4 ng/ml (0.2--0.8).007IL-12p40803 pg/ml (335--1374)228 pg/ml (106--294).008sCD40701 pg/ml (334--1162)264 pg/ml (168--396).008IL-189.8 ng/ml (5.7--25.7)4.9 ng/ml (3.7--9.1).008[^4]

Appendix A4Level of association in 101 cytokines, chemokines and complement factors with an unfavorable outcome in 15 Listeria meningitis patients compared to 11 Listeria meningitis patients with favorable outcome.VariableUnfavorable outcome (n = 15) median level (IQR)[a](#tf0030){ref-type="table-fn"}Favorable outcome (n = 11) median level (IQR)p-ValueEGF195 pg/ml (139--566)101 pg/ml (59--162)0.02CCL11688 ng/ml (442--942)292 pg/ml (152--425)0.005FGF21.4 ng/ml (0.9--1.6)699 pg/ml (338--1029)0.01Flt3-Lig264 ng/ml (62--321)241 pg/ml (114--282)0.80CX3CL17.6 ng/ml (1.2--14)761 pg/ml (608--1258)0.003GCSF8.3 ng/ml (5.8--16)14 ng/ml (4.0--18)0.68GMCSF497 pg/ml (208--1191)158 pg/ml (104--274)0.02CXCL12.7 ng/ml (1.1--9.9)2.2 ng/ml (1.7--3.7)0.84IFN-α21.4 ng/ml (0.9--1.9)658 pg/ml (323--897)0.005IL-1a1.5 ng/ml (0.4--3.0)383 pg/ml (317--451)0.04IL-1b151 pg/ml (96--591)206 pg/ml (71--430)0.92IL-1ra2.4 ng/ml (1.9--9.9)993 pg/ml (723--2718)0.03IL-234 pg/ml (25--98)37 pg/ml (24--93)0.92IL-316 pg/ml (8.2--32)14 pg/ml (6.5--31)0.99IL-470 pg/ml (35--100)64 pg/ml (20--104)0.76IL-510 pg/ml (7.3--14)10 pg/ml (5.4--21)0.99IL-650 ng/ml (28--99)59 ng/ml (14--78)0.57IL-7989 pg/ml (133--1764)123 pg/ml (69--174)0.04IL-812 ng/ml (5.3--26)7.2 ng/ml (6.1--16)0.92IL-9102 pg/ml (67--148)55 pg/ml (10--73)0.01IL-10439 pg/ml (175--1985)290 pg/ml (134--827)0.33IL-12p40803 pg/ml (335--1374)228 pg/ml (106--294)0.008IL-12p70146 pg/ml (81--216)98 pg/ml (53--203)0.47IL-137 pg/ml (8--48)42 pg/ml (14--74)0.36IL-1567 pg/ml (29--83)50 pg/ml (17--90)0.68IL-1743 pg/ml (16--58)37 pg/ml (19--115)0.99CCL220 ng/ml (6--31)7.0 ng/ml (2.7--10)0.84CCL71.1 ng/ml (0.6--7.4)653 pg/ml (436--1944)0.18CCL2215 pg/ml (248--1216)1.2 ng/ml (0.5--1.3)0.36CCL3394 pg/ml (154--663)155 pg/ml (107--209)0.07CCL41.7 ng/ml (1--4.2)1.0 ng/ml (0.5--5.2)0.51PDGFABBB100 pg/ml (51--328)178 pg/ml (83--336)0.36CCL598 pg/ml (23--219)48 pg/ml (28--199)0.76sCD40L701 pg/ml (334--1162)264 pg/ml (168--396)0.008sIL-2Rα426 pg/ml (159--573)119 pg/ml (65--159)0.002TGFα16.6 pg/ml (7.6--32)20 pg/ml (3.2--33)0.88TNFα331 pg/ml (242--771)307 pg/ml (108--558)0.33TNFβ272 pg/ml (28--622)25 pg/ml (18--55)0.04VEGF1.7 ng/ml (1.2--2.3)832 pg/ml (235--1134)0.001IL-189.8 ng/ml (5.7--26)4.9 ng/ml (3.7--9.1)0.008vWFAg7.8 pg/ml (4.1--20)2.5 pg/ml (1.3--3.9)0.02Fibrinog\\en0.6 pg/ml (0.5--0.6)0.2 pg/ml (0.2--0.6)0.03TAFI2.1 pg/ml (1.0--3)1.1 pg/ml (0.5--2.4)0.42CCL820 ng/ml (7.6--63)5.9 ng/ml (2.2--30)0.04CCL13239 pg/ml (96--392)301 pg/ml (189--397)0.91ENA-78474 pg/ml (282--680)470 pg/ml (386--740)0.35CXCL121.8 ng/ml (1.2--3.2)3.6 ng/ml (870--4.0)0.40CXCL1320 pg/ml (12--77)16 pg/ml (7.7--29)0.35CCL147 pg/ml (16--64)24 pg/ml (9.4--46)0.31IL-16298 pg/ml (198--515)247 pg/ml (158--464)0.66MIP-1d702 pg/ml (311--737)315 pg/ml (78--634)0.24CCL172.6 pg/ml (0.6--3.9)3.1 pg/ml (1.7--4.7)0.44CCL21613 pg/ml (140--1021)698 pg/ml (454--871)0.72CCL2475 pg/ml (19--102)45 pg/ml (24--62)0.24CCL2666 pg/ml (49--156)57 pg/ml (15--91)0.40CCL2751 pg/ml (9.6--74)9 pg/ml (5.9--38)0.15IL-23259 pg/ml (138--437)233 pg/ml (178--467)0.72LIF465 pg/ml (242--754)637 pg/ml (475--734)0.35TPO954 pg/ml (503--1291)859 pg/ml (513--1449)0.84TRAIL227 pg/ml (133--349)83 pg/ml (44--153)0.03SCF54 pg/ml (28--98)35 pg/ml (24--54)0.31TSLP71 pg/ml (27--116)76 pg/ml (54--97)0.78IL-201.6 ng/ml (0.8--2.9)1.8 ng/ml (1.5--2.7)0.49IL-2150 pg/ml (27--96)35 pg/ml (6.2--57)0.44IL-28A110 pg/ml (88--165)54 pg/ml (15--91)0.002[a](#tf0030){ref-type="table-fn"}IL-33161 pg/ml (99--184)96 pg/ml (64--157)0.08MCSF31 ng/ml (28--49)17 ng/ml (11--34)0.09CXCL79.1 ng/ml (5.8--11)3.2 ng/ml (1.7--5.2)0.003CXCL6658 pg/ml (111--1591)258 pg/ml (164--1171)0.97CCL14a13 ng/ml (5.5--19)6.2 ng/ml (4.3--7.6)0.11CCL19130 pg/ml (62--191)213 pg/ml (114--308)0.27CCL202.2 ng/ml (1.2--4.8)399 pg/ml (224--779)0.007XCL1675 pg/ml (362--1488)1.4 ng/ml (0.7--1.5)0.27IL-113.8 ng/ml (1.6--5.8)3.2 ng/ml (2.6--4.4)0.72IL-293.4 ng/ml (2.8--3.8)1.8 pg/ml (0.9--4.9)0.91MMP-323 ng/ml (10--42)23 ng/ml (7.9--37)0.76MMP-126.0 ng/ml (4.2--11)6.0 ng/ml (3.8--8.9)0.92MMP-133.4 ng/ml (2.3--6.3)5.4 ng/ml (3.2--7.8)0.12CFH7.5 ng/ml (4.2--11)6.0 ng/ml (5.4--8.0)0.27MMP-1892 pg/ml (345--1296)521 pg/ml (163--824)0.18MMP-216 ng/ml (6.2--32)22 ng/ml (9.3--33)0.54MMP-711 ng/ml (4.7--16)9.2 ng/ml (4.8--16)0.61MMP-9412 ng/ml (103--497)387 ng/ml (129--497)0.65MMP-10266 pg/ml (258--290)235 pg/ml (54--278)0.13ICAM83 pg/ml (59--136)52 pg/ml (43--92)0.11tPAI-150 pg/ml (28--101)51 pg/ml (28--77)0.92MIF1.3 ng/ml (0.6--5.0)1.5 ng/ml (0.6--6.9)0.57C3a338 pg/ml (139--500)112 pg/ml (62--170)0.002iC3b18.5 pg/ml (8.3--42)10 pg/ml (3.3--16)0.08C5a8 pg/ml (2.5--16)1.4 pg/ml (0.4--5.3)0.03C5b91.3 ng/ml (0.4--1.7)147 pg/ml (41--435)0.006[a](#tf0030){ref-type="table-fn"}IFN-γ15 ng/ml (5.2--41)2.7 pg/ml (1.4--16)0.04CXCL9392 ng/ml (62--582)57 ng/ml (20--252)0.09CXCL10488 ng/ml (487--488)487 ng/ml (476--488)0.84PDGFAA86 pg/ml (52--168)77 pg/ml (55--213)0.99CXCL1117 ng/ml (11--25)4.8 ng/ml (2.8--18)0.18C33.4 ng/ml (0.5--8.3)12 ng/ml (3.3--18)0.03VCAM3.9 ng/ml (2.7--5.5)3.3 ng/ml (3.0--5.3)0.96PAI-2279 ng/ml (221--342)171 ng/ml (165--301)0.06MBL11.0 ng/ml (3.9--23.5)11.9 ng/ml (5.0--14.9)0.75C1q176 ng/ml (130--295)144 ng/ml (40--215)0.22[^5] (See [Appendix A4](#t0025){ref-type="table"}.)
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![Levels of top 11 cytokines, chemokines and complement factors with strongest association with unfavorable outcome in patients with Listeria meningitis.\
Footnote: Dots indicate individual values, bars are medians and whiskers indicate interquartile range.](gr1){#f0005}

###### 

Clinical and laboratory characteristics on admission of 26 adults with community-acquired *L. monocytogenes* meningitis, 2006--2012 cohort [a](#tf0005){ref-type="table-fn"}.

  Variable                                                      Frequency
  ------------------------------------------------------------- -------------------
  Median age in years (IQR)                                     68 (57--74)
  Male sex                                                      20 (77)
  Predisposing factors                                          
   Immunocompromised                                            15 (58)
  Pre-treated with antibiotics                                  3 (12)
  Triad of fever, neck stiffness, and change in mental status   8 (31)
  Indexes of CSF inflammation                                   
   WBC count (cells/μL)                                         766 (225--2047)
   \< 1000 cells/mL                                             15 (58)
   Protein level (g/L)                                          2.4 (1.8--3.8)
   CSF to blood glucose ratio                                   0.27 (0.16--0.39)
  Dexamethasone treatment                                       14 (54)
  Neurological complications                                    19 (73)
  Systemic complications                                        15 (58)
  Unfavorable outcome                                           15 (58)
  Death                                                         6 (23)

Continuous data are presented as medians (interquartile range), dichotomous data are presented as n (%)

[^1]: Continuous data are presented as medians (interquartile range), dichotomous data are presented as n (%).

[^2]: Number of Listeria meningitis (LM) patients and number of negative controls (NC) for whom enough CSF was available to measure the analyte.

[^3]: Significantly elevated in *L. monocytogenes* meningitis patients compared to negative controls after Bonferroni correction (P \< 0.00051).

[^4]: IQR = interquartile range.

[^5]: Variable is significantly elevated in patients with Listeria meningitis with an unfavorable outcome compared to favorable outcome, but not compared to negative controls.
